ABVC - CIK 0001173313
The table below shows ABVC BIOPHARMA, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$894.24K | -$539.83K | -$955.82K | -$1.50M | -$2.99M | -$1.41M |
| Capital expenditure | - | - | - | - | $93.22K | - |
| Investing cash flow | $47.12K | - | - | - | -$93.22K | -$281.95K |
| Dividends paid | - | - | - | - | - |
ABVC BIOPHARMA, INC. reported operating cash flow of -$2.99M for fiscal year 2025. That is down 65.1% from -$1.81M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$3.47M (FY 2016) to -$2.99M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$342.18K | $428.76K | $924.15K | $2.21M | - | $42.23K |